Connect your AI

Humana HUM Proceeds from issuance of commercial paper and other short-term borrowings

Proceeds from issuance of commercial paper and other short-term borrowings at other companies

Elevance HealthELV

$724M—

Other financials

Income statement

Revenue$39.6B+23.5%

Operating income$1.8B-12.9%

Net income$1.2B-4.7%

EPS (diluted)$9.83-4.6%

Balance sheet

Cash & equivalents$5.0B+16.5%

Total debt$14.0B+5.2%

Total equity$18.6B+4.7%

Total assets$55.3B+8.5%

Cash flow

Operating cash flow$1.3B+279%

CapEx$121.0M+27.4%

Free cash flow$1.1B+380%

Valuation

Market cap$47.69B+64.5%

Enterprise value$56.73B+51.1%

P/E15×-1.9×

P/S0.4×+0.1×

Profitability

Operating margin2.7%-1.7pp

Net margin3%-0.1pp

FCF margin4.2%—

Returns & leverage

Return on equity18.2%+0.9pp

Debt / equity0.8×0.0×

Current ratio1.8×-0.1×

Where this comes from

Reported directly by Humana in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromShortTermDebt.

The official record: Humana’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Humana's proceeds from issuance of commercial paper and other short-term borrowings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Humana's proceeds from issuance of commercial paper and other short-term borrowings?: Humana (HUM) reported proceeds from issuance of commercial paper and other short-term borrowings of $0 in Q4 2025.